Navigation Links
Anticoagulant Drugs Had Similar Outcomes After Angioplasty
Date:3/30/2008

Study also finds drug-releasing stents appear to work better than uncoated ones

SUNDAY, March 30 (HealthDay News) -- In heart attack patients who had angioplasty, the anticoagulant drugs abciximab and tirofiban produced similar outcomes for certain cardiac measures within 90 minutes after the procedure, says an Italian study.

The researchers also found that patients who received coated stents that released the drug sirolimus had a lower risk of major adverse cardiac events within eight months than patients who received uncoated stents.

The study was to be presented Sunday at the American College of Cardiology annual meeting in Chicago. It was also to be published online Sunday in the Journal of the American Medical Association and will appear in the April 16 print issue.

Treatment with abciximab and implantation of an uncoated stent is a treatment strategy used to reduce the risk of major adverse cardiac events (MACE) in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI - a certain pattern on an electrocardiogram after a heart attack), according to background information in the study.

The researchers noted it hasn't been clear whether using tirofiban instead of abciximab would provide similar benefits. They added that the use of drug-eluting stents instead of uncoated stents in this patient population is discouraged because of safety concerns and conflicting evidence about efficacy.

In this study, Dr. Marco Valgimigli, of the Cardiovascular Institute at the University of Ferrara, and his colleagues compared high-dose tirofiban and sirolimus-releasing stents with abciximab infusion and uncoated stents in 745 patients with STEMI undergoing angioplasty. They found that ST-segment elevation was reduced by at least 50 percent within 90 minutes after angioplasty in 83.6 percent of patients in the abciximab group and in 85.3 percent of those in the tirofiban group.

At eight months, the MACE rate among those treated with tirofiban was 9.9 percent, compared to 12.4 percent in the abciximab group. The MACE rate among patients who received uncoated stents was 14.5 percent, compared with 7.8 percent among those who received the drug-releasing stent. The rate of revascularization (a repeat procedure to unblock a blood vessel) was 3.2 percent among patients who received the drug-coated stent, compared with 10.2 percent among patients who received an uncoated stent.

"In summary, our study provides evidence that in a broad population of largely unselected patients undergoing PCI for STEMI, tirofiban therapy is associated with a noninferior resolution from ST-segment elevation at 90 minutes post-intervention compared with abciximab, and at eight-month follow-up, MACE are approximately halved by sirolimus-eluting stent implantation compared with uncoated stents," the study authors wrote.

More information

The U.S. National Heart, Lung, and Blood Institute has more about angioplasty.



-- Robert Preidt



SOURCES: JAMA/Archives journals, news release, March 30, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Different anticoagulant regimens yield equal results
2. Comparison of anticoagulants for angioplasty show similar outcomes
3. New review suggests caution on drugs to raise good cholesterol
4. Can cancer drugs combine forces?
5. Study provides hope that some transplant patients could live free of antirejection drugs
6. Study provides hope that some transplant patients could live free of anti-rejection drugs
7. RA Drugs Linked to Slight Skin Cancer Risk
8. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
9. Rock N Roll: Sex, Drugs and an Early Exit
10. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anticoagulant Drugs Had Similar Outcomes After Angioplasty
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: